This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
Liver Metabolism and Nonalcoholic Fatty Liver Disease (NAFLD)
joint with Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure
Organizer(s): Jay D. Horton, Douglas G. Mashek and Brian N. Finck
Date: March 22 - 27, 2015
Location: Fairmont Chateau Whistler, Whistler, BC, Canada
Sponsored by Intercept Pharmaceuticals, Inc., Merck & Co., Inc., Regeneron Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited
Summary of Meeting:
Abnormalities in hepatic intermediary metabolism are common in obesity and are a significant source of morbidity and mortality in obese people. For example, nonalcoholic fatty liver disease (NAFLD) affects over 25% of the US population and has become the most common cause of liver failure and transplantation. NAFLD is also linked to the development of major metabolic diseases such as type 2 diabetes and cardiovascular diseases. Despite the central role of the liver in whole-body energy metabolism and its contribution to disease development, there are literally no dedicated meetings that focus on the cellular and mechanistic aspects of the regulation of liver metabolism. This meeting will bring together experts, both basic scientists and clinicians, across diverse fields including biochemistry, cell biology, genetics, hepatology, nutrition, physiology and virology to exclusively focus on the liver and bridge a translational divide. Meeting themes will center on regulation of hepatic energy metabolism, crosstalk between the liver and different organs and cell types and how alterations in macronutrient metabolism contribute to disease etiology. The objectives of this conference are to: 1) Expose scientists across diverse disciplines to different aspects of hepatic metabolism and NAFLD development; 2) Find synergies in research efforts to expedite our understanding of hepatic energy metabolism; and 3) Explore emerging metabolic targets for therapeutic interventions to prevent or alleviate NAFLD and related comorbidities.
Scholarship Deadline: November 20 2014
Discounted Abstract Deadline: November 20 2014
Abstract Deadline: December 18 2014
Discounted Registration Deadline: January 21 2015
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Intercept Pharmaceuticals, Inc.Merck & Co., Inc.Regeneron Pharmaceuticals, Inc.Takeda Pharmaceutical Company Limited
We gratefully acknowledge additional support for this conference from:
Lilly USA, LLC
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Genentech, Inc.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found